The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2016Alpha-synuclein Toxicity in LRRK2 Pre-clinical Models and Rescue by LRRK2 Silencing
Study Rationale:
Genetic mutations that alter the function of the LRRK2 protein increase the risk of developing a form of Parkinson's disease (PD). Age and other environmental factors combine with... -
Proof-of-Concept Testing of PD Therapeutics, 2022Therapeutic Targeting of Mitochondrial Biogenesis to Address Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a complex disorder involving the degeneration of specific brain cells that lead to severe impairments in movement and cognition. Although the exact cause...
-
Rapid Response Innovation Awards, 2012A Genetic Strategy to Restore Impaired Noradrenergic Function by Increasing Expression of Noradrenergic Phenotypes in the Locus Coeruleus in Parkinson’s Disease Pre-clinical Models
Objective/Rationale:
Compelling evidence demonstrated that a dysfunction of the locus coeruleus (LC)-
noradrenaline (NE) system in the brain not only contributes to alterations in
cognitive and motor... -
Parkinson’s Disease Therapeutics Pipeline Program, 2024Assessment of IRL757 for the Treatment of Apathy in Parkinson's Disease
Study Rationale: People with Parkinson’s disease (PD) frequently develop a loss of motivation and initiative. Such apathy can be burdensome for patients and their families and caregivers and is...
-
Fast Track, 2001PET Neuroimaging Study of the Brain Serotonin Transporter in Parkinson's Disease: Relationship to Clinical Depression
Approximately 40% of patients with Parkinson's disease (PD) suffer from depression, which in many cases is more disabling than the impairment of motor function. Since the original discovery by Oleh...
-
LRRK2 Cohort Consortium Resource Request, 2013Cortical and Subcortical Changes in Non-manifesting Carriers of the G2019S Mutation in the LRRK2 Gene
Objective/Rationale:
Imaging techniques such as DaT SPECT, FDG PET and magnetic resonance imaging (MRI) have frequently been used to assess Parkinson’s disease (PD) changes in parts of the brain called...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.